Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: A report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation

Bone Marrow Transplantation

Volumn 49, Issue 3, 2014, Pages 389-396

  Baron, F ^a   Labopin, M ^b,c,d   Blaise, D ^e   Lopez Corral, L ^f   Vigouroux, S ^g   Craddock, C ^h   Attal, M ⁱ   Jindra, P ^j   Goker, H ^k   Socie G ^l   Chevallier, P ^m   Browne, P ⁿ   Sandstedt, A ^o   Duarte, R F ^p   Nagler, A ^q   Mohty, M ^b,c,d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j CHARLES UNIVERSITY   (Czech Republic)

^k HACETTEPE UNIVERSITY   (Turkey)

^l SAINT LOUIS HOSPITAL   (France)

^m NANTES UNIVERSITY HOSPITAL   (France)

ⁿ ST JAMES S HOSPITAL   (Ireland)

^o LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^p HOSPITAL DURAN I REYNALS   (Spain)

^q TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

alemtuzumab; AML; ATG; GVHD; reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; BUSULFAN; MELPHALAN; THYMOCYTE ANTIBODY; HLA ANTIGEN; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; GRAFT REJECTION; HLA MATCHING; HUMAN; LEUKEMIA RELAPSE; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; ALLOTRANSPLANTATION; BLOOD; CLINICAL TRIAL; CYTOLOGY; DONOR; EUROPE; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; SIBLING; STEM CELL; T LYMPHOCYTE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; MELPHALAN; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SIBLINGS; STEM CELLS; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904242565     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.204     Document Type: Article

References (41)

1. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
2. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005; 23: 5074-5087.
3. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012; 367: 1487-1496.
4. Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR et al. Mobilized peripheral blood stem cells compared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with r educed-intensity conditioning in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012; 18: 1422-1429.
5. Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006; 12: 573-584.
6. Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab. Biol Blood Marrow Transplant 2007; 13: 724-733.
7. Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Frese-nius. Blood 2011; 117: 6375-6382.
8. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
9. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-ver-sus-tumor effects. Blood 2001; 97: 3390-3400.
10. Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
11. Sandmaier BM, Mackinnon S, Childs RW. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant 2007; 13: 87-97.
12. Baron F, Storb R. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol 2007; 14: 145-151.
13. Baron F, Petersdorf EW, Gooley T, Sandmaier BM, Malkki M, Chauncey TR et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant 2009; 15: 580-588
14. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Seattle Marrow Transplant Team. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
15. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584.
16. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003.
17. Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 2012; 18: 1727-1733.
18. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C et al. Impact of graft-versus-host disease after reduced-intensity conditioning allo-geneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012; 26: 2462-2468.
19. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963-6970.
20. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
22. Giebel S, Labopin M, Mohty M, Blaise D, Craddock C, Nagler A et al. The impact of center experience on results of reduced intensity-Allogeneic Hematopoietic Stem Cell Transplantation. a survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2010; 116: 1445-1446.
23. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA et al. Non-myeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 2859-2867.
24. Mohty M, Labopin M, Balere ML, Socie G, Milpied N, Tabrizi R et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia 2010; 24: 1867-1874.
25. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387-1394.
26. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470-476.
27. Crocchiolo R, Esterni B, Castagna L, Furst S, El-Cheikh J, Devillier R et al. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases. Cancer 2012; 119: 986-992.
28. Devillier R, Crocchiolo R, Castagna L, Furst S, El CJ, Faucher C et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 639-645.
29. Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 105: 4532-4539.
30. Delgado J, Canals C, Attal M, Thomson K, Campos A, Martino R et al. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia 2011; 25: 551-555.
31. Michallet M, Le QH, Mohty M, Prebet T, Nicolini F, Boiron JM et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Exp Hematol 2008; 36: 535-544.
32. Baron F, Labopin M, Mufti GF, Arnold R, Craddock C, Bilger K et al. Impact of alemtuzumab versus anti-thymocyte globulin (ATG) after unrelated allogeneic stem cell transplantation (allo-SCT) with reduced intensity conditioning (RIC) as treatment for AML in CR1: a survey from the acute leukemia working party of the EBMT. Bone Marrow Tranplant 2012; 47: 75-76.
33. Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim Z, Pearce RM et al. Outcomes following Donor lymphocyte infusions post-T-cell depleted allogeneic haematopoietic Stem cell transplants for acute myeloid leukaemia and myelo-dysplastic syndromes. Biol Blood Marrow Transplant 2013; 19: 562-568.
34. Peggs KS, Thomson K, Hart H, Geary J, Morris EC, Yong K et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism and disease responses. Blood 2004; 103: 1548-1556.
35. Liga M, Triantafyllou E, Tiniakou M, Lambropoulou P, Karakantza M, Zoumbos NC et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Biol Blood Marrow Transplant 2013; 19: 75-81.
36. Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012; 119: 3361-3369.
37. Mohty M, Chevallier P. Azacitidine after allo-SCT: the good without the bad? Blood 2012; 119: 3199-3200.
38. Chevallier P, Labopin M, Milpied N, Cornelissen JJ, Blaise D, Petersen E et al. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant 2012; 47: 1442-1447.
39. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878-1887.
40. Randolph SSB, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic cell transplants. Blood 2004; 103: 347-352.
41. Giebel S, Labopin M, Mohty M, Mufti GJ, Niederwieser D, Cornelissen JJ et al. The impact of center experience on results of reduced intensity: allogeneic hemato-poietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplant 2013; 48: 238-242.